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Abstract: The incidence of Clostridium difficile infection (CDI) in pediatric patients continues 
to rise. Most of the pediatric recommendations for CDI treatment are extrapolated from the 
literature and guidelines for adults. The American Academy of Pediatrics recommends oral 
metronidazole as the first-line treatment option for an initial CDI and the first recurrence if 
they are mild to moderate in severity. Oral vancomycin is recommended to be used for severe 
CDI and the second recurrent infection. Additional pulsed regimen of oral vancomycin, which 
is tapered, may increase efficacy in refractory patients. However, there is lack of large studies 
evaluating the use of fidaxomicin in pediatrics to know whether it could be a safe and effective 
treatment option for difficult-to-treat patients. Fidaxomicin is associated with higher total drug 
costs compared to metronidazole and vancomycin, but the literature supports its use due to a 
lower rate of CDI recurrence, which may result in cost savings. Further studies are warranted 
to evaluate the use of fidaxomicin in patients <18 years old and to understand its role in the 
standard of care for pediatric patients with CDI.
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Introduction
Clostridium difficile is a spore-forming, anaerobic, Gram-positive bacillus. Humans 
acquire C. difficile from their environment or via the oral–fecal route, which can 
lead to infection. C. difficile produces two toxins: toxin A and toxin B.1 C. difficile is 
the most frequent cause of antimicrobial-associated diarrhea. The disruption of the 
body’s normal flora, often as a result of antimicrobial treatment, leads to overgrowth 
of C.  difficile, toxin production, and disease development.2
C. difficile testing in infants <1 year of age is not recommended due to the high 
rates of colonization. Studies have shown that 37% of infants who are <1 month old 
are colonized with C. difficile and are asymptomatic.3 The toxins produced by the 
organism are important for disease pathogenesis and infection. As the child ages, 
the rates of C. difficile colonization decrease. A recent study reported 30% and 14% 
colonization rates in infants aged 1–6 months and 6–12 months, respectively.3 If testing 
were to be completed and the results were positive, additional workup is recommended 
to identify other alternative causes of diarrhea due to the rare incidence of disease in 
this age group. By 2 years of age, normal flora in the lower intestine is established 
similar to that of adults.2
The exposure to antibiotics is the most important risk factor for an initial CDI.4 
Penicillins, cephalosporins, clindamycin, and fluoroquinolones are associated more 
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commonly with CDI, whereas sulfonamides, tetracyclines, 
vancomycin, metronidazole, and aminoglycosides are less 
commonly linked in children. Pediatric patients who are 
exposed to multiple antibiotics from different classes in the 
previous 30 days have been shown in recent studies to be 
associated with severe and recurrent CDI.5,6 Other risk fac-
tors include acid-suppressing medications, such as proton 
pump inhibitors, and use of gastrointestinal feeding tubes.7,8
The risk factors for an initial CDI are similar to the 
risk factors for recurrent infections. Retrospective studies 
have associated an increased risk of recurrence in patients 
with complex medical conditions, cancer, recent surgery, 
or hospitalization and in those who were treated with any 
non-CDI antibiotics during the time of CDI treatment.6,9,10 
Another retrospective study conducted by Lo Vecchio et al11 
found that metronidazole has a five-fold increase in the risk 
of recurrent infection (OR =5.18, p=0.03). The reasons for 
treatment failure with metronidazole are not well understood. 
It has been hypothesized that as inflammation in the colon 
decreases following the initial few days of treatment, the 
concentration of metronidazole in the stool decreases due 
to higher levels of systemic absorption.12
The strain of C. difficile that has been associated with 
causing more severe disease in the late 2000s is the NAP1.13 
Studies have shown that NAP1 accounts for 10%–19% of 
C. difficile isolates. The epidemiology of CDI may be chang-
ing as a result of this strain because pediatric patients are 
developing severe CDI with no prior exposure to antibiotics 
or health care facilities.14 Isolate identification alone does not 
change care, but it can influence the therapeutic decision-
making process by accounting for potential drug resistance.13 
Even though the NAP1 strain may have reduced role in the 
USA nowadays, this strain is still found to predict clinical 
outcomes in patients with CDI.15,16 Further studies are needed 
to determine whether the NAP1 strain or other strains are the 
reasons for more severe disease in children.
Classifying the severity of CDI based on clinical signs and 
symptoms is essential to treatment selection. Patients with 
mild CDI have mild diarrhea, which is defined as having three 
to five unformed stools per day, in addition to being afebrile 
and lacking notable laboratory abnormalities.17,18 Moderate 
CDI is often associated with nausea and vomiting, dehydra-
tion, white cell count >15,000/mm3, and elevated blood urea 
nitrogen and serum creatinine levels. Patients with severe CDI 
have severe or bloody diarrhea, pseudomembranous colitis, 
severe abdominal pain, fever, white cell count >20,000/mm3, 
albumin <2.5 mg/dL, and acute kidney injury. Complications 
of severe CDI include toxic megacolon, peritonitis, ileus, 
respiratory distress, hemodynamic instability, and end organ 
failure.17,18 However, these disease complications are not seen 
as often in children as in adults.19 In addition, it is important 
to note that disease severity can be overestimated if adult 
criteria for severe disease are used in children.20
The incidence of CDI in children has increased in the 
USA over the past few decades. Kim et al21 conducted a 
5-year retrospective cohort study of pediatric patients hospi-
talized with CDAD in the USA. From 2001 to 2006, there was 
an increase in cases per 1,000 admissions (from 2.6 to 4.0; 
53%; p=0.04) and cases per 10,000 patient-days (from 4.4 
to 6.5; 47%; p=0.06). Nylund et al22 demonstrated a similar 
upward trend in cases of CDI, from 3,565 cases in 1997 to 
7,779 cases in 2006 (14.9% per year, p<0.01). Recent stud-
ies, however, did not find any increases in severity of CDI 
and outcome measures such as colectomy or mortality.21–23 In 
order to help contain the spread of C. difficile and minimize 
the cases of CDI, it is recommended that clinicians should 
use gloves when caring for patients, wash hands with soap 
after caring for patients, and use germicidal wipes with 
10% sodium hypochlorite for cleaning the contaminated 
environment.24
Standard of care
The AAP published a policy statement in 2013 giving provid-
ers guidance on how to effectively treat patients with CDI; 
however, only oral vancomycin is approved by the US FDA 
for use in pediatric CDI.25 Many of the recommendations 
made by the AAP are extrapolated from adult guidelines pub-
lished by the SHEA and the IDSA.18 For all types of CDI, the 
AAP recommends stopping offending antimicrobial agents, 
if possible. For treatment of initial occurrence and first recur-
rence of mild-to-moderate disease, oral metronidazole 30 mg/
kg/d in four divided doses (maximum dosage of 2 g/d) is the 
drug of choice over oral vancomycin and oral fidaxomicin.18 
Metronidazole is the preferred agent because of its efficacy 
against VRE and its lower cost for the patients.26,27 If a child 
has severe CDI or has a second recurrence of CDI, the treat-
ment of choice is oral vancomycin 40 mg/kg/d in four divided 
doses (maximum dosage of 500 mg/d).28 If the patient has 
not improved after 24–48 hours, the oral vancomycin dose 
may be increased to a maximum dosage of 2 g/d. Intravenous 
metronidazole (30 mg/kg/d) may be added to intracolonic 
vancomycin dosed every 6 hours for severely ill patients with 
ileus, who may not be able to tolerate oral antibiotics.29,30 
According to expert opinions, enema volumes should be age 
dependent for pediatric patients (250 mg of vancomycin in 
50 mL of normal saline for 1- to 3-year-old children; 375 mg 
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in 75 mL for 4- to 9-year-old children; and 500 mg in 100 mL 
for ≥10-year-old patients).31 This regimen may help achieve a 
clinical cure in difficult-to-treat patients29 (Figure 1).
Some patients may develop another CDI infection after 
their initial clinical cure. Patients who have recurrent CDI 
that is not severe can be treated with metronidazole, and 
this decision should not be influenced by their previous 
drug exposure.18 Vancomycin can be selected over metroni-
dazole if the recurrent CDI episode appears to be clinically 
more severe than the initial episode. Oral fidaxomicin can 
potentially be an alternative treatment option for the first 
recurrence of nonsevere CDI, but major studies evaluating 
its use in pediatric patients are lacking.25
Patients who are having multiple recurrences of CDI 
may benefit from tapering and pulsed oral vancomycin.32 In 
adults, patients initially receive 125 mg four times daily for 
7–14 days. The taper then proceeds as follows: 125 mg twice 
daily for 7 days, 125 mg once daily for 7 days, 125 mg every 
Figure 1 Treatment algorithm for Clostridium difficile infection in pediatric patients.
Notes: aThe European guideline only recommends treatment in patients with moderate infection; bif single dose is ≥125 mg based on the 40 mg/kg/d divided-four-times 
dosing; cbased on limited clinical data and case reports in pediatric patients. Data from previous studies.2,17,18,31,33
Abbreviations: C. difficile, Clostridium difficile; CDI, Clostridium difficile infection; ICU, intensive care unit; WBC, white blood cells.
CDI:
• Diarrhea (≥3 loose stools in 24 hours)
• Positive stool test for C. difficile toxin (consider potential
for colonization)
Stop offending antimicrobial agents, if possible
Mild-to-moderate disease:a
Mild: afebrile, mild abdominal
discomfort/tenderness, no notable
laboratory abnormalities
Moderate: nonbloody diarrhea, moderate
abdominal discomfort/tenderness, nausea
with occasional vomiting, dehydration, WBC
>15,000 cells/mm3, blood urea nitrogen or
creatinine levels above baseline
Severe disease:
Severe or bloody diarrhea,
pseudomembranous colitis, severe
abdominal pain, vomiting, temperature
>38.5°C, WBC >20,000 cells/mm3, albumin
level <2.5 mg/dL, and acute kidney injury 
Severe and complicated:
Any of the following attributable to CDI:
• Toxic megacolon
• Peritonitis
• Ileus or significant abdominal distension
• Respiratory distress
• Hemodynamic instability
• ICU admission for CDI
• End organ failure
Vancomycin (oral) 40 mg/kg/d, divided
every 6-8 hours (maximum dose 500 mg/d)
for 10 days
Metronidazole (oral) 30 mg/kg/d,
divided every 6 hours (maximum
2 g/d) for 10 days 
Vancomycin (oral) 40 mg/kg/d, divided every 6–8 hours
(maximum dose 500 mg/d) for 10 days
AND
Metronidazole (intravenous) 30 mg/kg/d, divided every 8
hours (maximum 2 g/d)
Vancomycin (oral) 40 mg/kg/d, divided
every 6–8 hours (maximum dose 2 g/d)
for 10 days
Vancomycin (oral) 40 mg/kg/d,
divided every 6–8 hours (maximum
dose 500 mg/d) for 10 days
If not improving after
5–7 days
If not improving after
24–48 hours
Vancomycin (per rectal retention enema), dosed every 6 hours:
• 250 mg in 50 mL normal saline (1–3 years old); 375 mg in
75 mL (4–9 years old); 500 mg in 100 mL (≥10 year old)
AND
Metronidazole (intravenous) 30 mg/kg/d, divided every 8 hours
(maximum 2 g/d)
No significant
abdominal distension
If complicated with ileus or toxic colon and/or
significant abdominal distension
First recurrence Second recurrence
Metronidazole (oral) 30 mg/kg/d, 
divided every 6 hours (maximum 2
g/d) for 10 days 
Mild-to-moderate disease Severe disease
Vancomycin (oral) 40 mg/kg/d, 
divided every 6–8 hours (maximum
dose 500 mg/d) for 10 days
Vancomycin (oral) pulsed and tapered:b
• 125 mg every 6 hours for 7–14 days
• 125 mg twice daily for 7 days
• 125 mg once daily for 7 days
• 125 mg every other day for 7 days
• 125 mg every 3 days for 14 days
Potential
alternative
agentc
≥6 years old: fidaxomicin (oral) 200 mg
twice daily for 10 days
Potential
alternative
agentc
≥6 years old: fidaxomicin (oral) 200 mg
twice daily for 10 days
If not improving after
24–48 hours
Vancomycin (oral) 40 mg/kg/d, divided every
6–8 hours (maximum dose 2 g/d) for 10 days
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other day for 7 days, and finally, 125 mg every 3 days for 
14 days. This dosing scheme has not yet been validated in 
pediatric patients, but most experts will usually extrapolate 
it to their patients when the single dose is ≥125 mg based on 
the 40 mg/kg/d divided-four-times dosing (Figure 1). Oral 
fidaxomicin may also have a role in patients who are having 
multiple recurrences because studies have reported that it 
provided a low recurrence rate compared to the standard regi-
men of vancomycin.32 Table 1 summarizes the recommended 
medication doses for CDI treatment in pediatric patients.
Unlike the recommendation by the AAP, the guidelines 
for the management of acute gastroenteritis in children, 
developed by the European Society for Pediatric Gastroen-
terology, Hepatology, and Nutrition as well as the European 
Society for Pediatric Infectious Diseases, only recommend 
antibiotic therapy for moderate and severe cases of CDI.33 
For patients who have mild antibiotic-associated CDI, their 
recommendation is to discontinue the antibiotic being used. 
Oral metronidazole is still the first-line treatment option, 
reserving vancomycin as an alternative when resistant strains 
to metronidazole are known or anticipated.33
Pharmacology
Metronidazole is an antibiotic used in the treatment of 
anaerobic bacterial infections. It acts by diffusing into the 
organism and causing DNA strand breakage and a loss of 
its helical structure, altering the organism’s DNA.34 These 
effects on DNA inhibit protein synthesis and lead to cell 
death. When given orally, metronidazole is well absorbed, 
with a bioavailability of >90%. It distributes widely in the 
body, so that small quantities reach the colon, which may be 
a disadvantage pharmacodynamically for CDI.35 Poor blood 
flow from the systemic circulation to the colonic mucosa is 
a hypothesized reason for why metronidazole can be less 
effective at treating severe CDI. The liver metabolizes the 
parent compound to five metabolites, including the active 
hydroxyl metabolite, which has ~30%–65% activity and a 
longer half-life than the parent drug. Dose adjustments should 
be made for patients with liver disease due to a decrease in 
clearance of metronidazole.35 The drug is eliminated from the 
body through both urine and feces, with a half-life between 
6 and 10 hours.34 Therefore, metronidazole should be given 
at higher doses less frequently due to its concentration-
dependent bactericidal activity, prolonged half-life, and 
sustained activity.35
Vancomycin is a glycopeptide antibiotic that acts by 
inhibiting bacterial cell wall synthesis by tight binding to 
the d-alanyl-d-alanine portion of the cell wall precursor 
and blocking glycopeptide polymerization.36 When given 
orally, the systemic absorption of vancomycin is poor, and 
maximum drug concentrations remain localized to the gut, 
which is a major pharmacokinetic advantage compared to 
Table 1 Dosing of medications for CDAD in pediatric patients
Medications US FDA 
approved
Route Recommended dose Maximum 
dose
Duration
Metronidazole No; off-label use Oral Mild-to-moderate CDAD: 30 mg/kg/d, divided every 6 hours 2 g/d 10–14 days
IV Complicated CDAD: 30 mg/kg/d, divided every 8 hours (used with oral 
or intracolonic vancomycin)
Vancomycin Yes Oral Severe: 40 mg/kg/d, divided every 6–8 hours 500 mg/d 7–14 days
Severe – not improving after 24–48 hours: 40 mg/kg/d, divided every 
6 hours 
2 g/d
Severe, recurrent: 
(Tapered and pulsed) 
125 mg every 6 hours for 7–14 days 
125 mg twice daily for 7 days 
125 mg once daily for 7 days 
125 mg every other day for 7 days
125 mg every 3 days for 14 days 
N/A 42–49 days
No; off-label use Rectal Complicated: 
 Intracolonic retention enema: dosed every 6 hours in normal saline
250 mg in 50 mL for 1- to 3-year-old patients
375 mg in 75 mL for 4- to 9-year-old patients
500 mg in 100 mL for ≥10-year-old patients
(used with IV metronidazole)
N/A 7–14 days
Fidaxomicin No; off-label use Oral ≥6-year-old patients: 200 mg twice daily* Same 10 days
Notes: *US FDA-approved adult dosing; based on data from a pharmacokinetic study41 in pediatric patients. Data from previous studies.18,28–32,41
Abbreviations: CDAD, Clostridium difficile-associated diarrhea; US FDA, United States Food and Drug Administration; IV, intravenous; N/A, not applicable.
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metronidazole.37 Oral vancomycin is eliminated from the 
body primarily through the feces.36 Serum vancomycin 
concentrations are typically undetectable if vancomycin is 
dosed orally at 125 mg every 6 hours.37 Higher doses, such 
as 500 mg every 6 hours, have been shown to result in higher 
serum concentrations (ie, 1.0–5.1 µg/mL).37 The use of pulsed 
vancomycin therapy may make the spores susceptible to the 
antibiotic when it is readministered, and prolonged treatment 
duration may also be important for clinical cure.32
Fidaxomicin is a novel macrolide antibiotic that acts on 
susceptible organisms, including C. difficile, by inhibiting 
the sigma subunit of RNA polymerase and, thereby, protein 
synthesis.38 Fidaxomicin is bactericidal and has postantibiotic 
activity, which may result in lower rates of CDI recurrence.39 
This medication is administered orally and remains largely 
confined to the GI tract, resulting in minimal systemic 
absorption. The parent drug is metabolized by intestinal 
hydrolysis to a less-active metabolite (ie, OP-1118). The 
first pharmacokinetic study with fidaxomicin in children 
confirmed the minimal systemic absorption of fidaxomicin 
following oral administration, with desired plasma concen-
trations of fidaxomicin (mean: 13.36 ng/mL) and OP-1118 
(mean: 60.16 ng/mL at 1–2 hours postdose) at therapeutic 
doses.40,41 These plasma concentrations were similar across all 
pediatric ages. Fidaxomicin is eliminated primarily through 
the feces, which was confirmed in children by the high fecal 
concentrations of the parent drug (mean: 3,227.93 µg/g) and 
OP-1118 (mean: 865.49 µg/g) after multiple dosing. There 
was a trend toward higher fecal concentrations in patients 
<6 years of age.40,41 The pharmacokinetics of fidaxomicin in 
children was similar to that reported in adults (ie, elimination 
half-life, t
1/2
 =0.94–2.77 hours; maximum observed serum 
concentration, C
max 
=5 ng/mL; time taken to reach C
max
, T
max 
=2 hours; area under the concentration–time curve, AUC 
=48.3 ng-h/mL).41,42
Safety and tolerability
The safety and tolerability of metronidazole and vancomycin 
in pediatric patients is not well documented in the literature. 
Metronidazole and vancomycin have been well studied in 
adult patients, and the safety and tolerability data are extrapo-
lated from adults to support their use in pediatric patients. A 
2015 meta-analysis and systematic review included 17 studies 
from 13 articles (n=2,501) assessing the safety of oral met-
ronidazole monotherapy with oral vancomycin monotherapy 
and combination therapy in adult patients with mild or severe 
CDI.43 The studies did not show any statistically significant 
difference in the incidence of adverse effects between oral 
metronidazole and vancomycin (OR =1.18, p=0.41). The 
studies that compared monotherapy regimens to combina-
tion therapy regimens reported a significantly lower amount 
of adverse effects for either monotherapy option (OR =0.30, 
p<0.0001). Limitations of this analysis include a relatively 
small sample size of each subgroup when the total sample size 
was divided for defined comparisons, and follow-up times 
also varied among studies (3–12 weeks), which could have 
affected the results.43 Otherwise, common side effects of oral 
metronidazole include dose-dependent peripheral neuropathy 
and metallic taste as a result of systemic absorption.34 Oral 
vancomycin has minimal systemic absorption, which leads 
to a higher incidence of gastrointestinal symptoms such as 
nausea, abdominal pain, and vomiting.36
Fidaxomicin has not been studied extensively in pediatric 
patients. In 2014, an open-label study treated children aged 
6 months to <18 years with fidaxomicin.40,41 This was the first 
study of fidaxomicin in children. Children <6 years of age 
were given 32 mg/kg/d of fidaxomicin divided twice daily 
(up to the adult dose, which is 200 mg twice daily). Children 
6 years or older were given the recommended adult dose. 
There is a warning associated with fidaxomicin for patients 
who have a known allergy to macrolides because they may be 
at increased risk for sensitivity to fidaxomicin.39 Fidaxomicin 
has been found to be well tolerated in children and has very 
low rates of systemic side effects, which may positively affect 
treatment by increased compliance.44 However, 73.7% of 
the participants had at least one adverse event, mostly mild 
and moderate (44.7% and 21.1%, respectively). Adverse 
events reported include upper abdominal pain, constipation, 
diarrhea, nausea, and vomiting. This incidence of adverse 
events is more likely and expected in pediatric patients with 
an underlying moderate-to-severe CDI, and it is difficult to 
determine whether the adverse effects are from the drug or are 
the symptoms of the CDI. One limitation of the study is that 
fecal concentrations were only evaluated on the last day of 
therapy, which did not allow clinicians to determine whether 
fecal concentrations were at the desired levels throughout the 
duration of treatment.40,41
Efficacy
Efficacy data on the use of standard therapy for CDI in pediat-
ric patients are limited, whereas the efficacy of metronidazole 
and vancomycin in the treatment of CDI in adults has been 
reported in the literature for decades.28,45 It is, however, impor-
tant to evaluate some of these adult data in order to derive 
how pediatric patients with CDI are being treated. Early 
studies were conducted to establish optimal dosing to be used 
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in  clinical practice. Fekety et al45 conducted a randomized 
trial that compared two dosing regimens of vancomycin in 
hospitalized patients with nonsevere CDI (n=46, mean age: 
54 years). The primary objective was treatment response, and 
the secondary objective was CDI recurrence. Patients were 
stratified according to probable colitis and definite colitis 
diagnosis and were randomized to one of two oral vanco-
mycin dosing regimens. Oral vancomycin dosed at 125 mg 
every 6 hours was found to be noninferior to 500 mg every 
6 hours for the treatment of nonsevere CDI (87.5% vs 95.4%, 
respectively, c2=1.36, p>0.05). Interestingly, one infant 
(unknown weight) was included in this study and responded 
well to 20 mg of oral vancomycin dosed at every 6 hours (an 
equivalent dose to the adult dosing based on body surface 
area). Because both regimens are equally effective and the 
500 mg regimen is more expensive, the 125 mg regimen is 
preferred. One limitation of the study is the small sample size, 
which might have prevented the higher dose regimen from 
being seen as superior. Another limitation could be the lack 
of stratification for the severity of illness and the inability to 
determine whether the higher dose would have been more 
effective in the severely ill patients.45
Metronidazole is used as an effective, first-line treatment 
option for initial and first recurrence of mild-to-moderate CDI 
and is preferred over oral vancomycin. There have been reports 
of treatment failure in patients treated with oral metronidazole, 
which presents the need for further evaluation of the most 
appropriate first-line agent. Zar et al28 conducted a prospec-
tive, randomized, double-blind, placebo-controlled trial com-
paring oral metronidazole to oral vancomycin. Hospitalized 
patients were enrolled from October 1994 through June 2002 
and stratified according to mild or severe disease based on 
clinical criteria. Thus, 172 patients (mean age: 58 years) were 
randomly assigned to receive oral metronidazole (250 mg four 
times daily) or oral vancomycin (125 mg four times daily) 
for 10 days. The primary outcomes were cure, treatment 
failure, and relapse after 21 days. In patients with mild CDI, 
the cure rates with metronidazole and vancomycin were 90% 
and 98%, respectively (p=0.36). In patients with severe CDI, 
the cure rates with metronidazole and vancomycin were 76% 
and 97%, respectively (p=0.02). One limitation of the study 
is that the participants had a 12.5% dropout rate, which could 
present attrition bias, but the study still achieved its defined 
power. The results demonstrated that both treatments can be 
used effectively for mild CDI; however, the superiority of 
vancomycin supports its use as the drug of choice for treating 
patients with severe CDI.28
Published data on the efficacy of fidaxomicin in children 
with mild or severe CDI are very limited. A 2013 case 
report demonstrated successful treatment with fidaxomicin 
in a 10-year-old child (unknown weight) with recurrent 
CDI.46 The patient had exposure to multiple antibiotic treat-
ments for recurrent pneumonia and, as a result, had five 
previous episodes of CDI over a 1-year period. Previous 
recurrent infections were treated with oral vancomycin. 
The providers decided to treat this recurrent CDI with 
200 mg of fidaxomicin twice daily for 10 days, and the 
tablets were crushed, mixed with water, and given via a 
gastrostomy tube. After 24 hours of treatment with fidax-
omicin, the patient’s diarrhea improved, and he was able 
to be discharged home on the third day of his admission. 
Clinical cure was achieved and maintained for several 
months. The patient was treated with clarithromycin for 
a recurrent pneumonia, which resulted in another CDI. 
Fidaxomicin treatment was used a second time and once 
again had an effective response.46
Fidaxomicin is a potential treatment option for recurrent 
infections and for patients with severe CDI. Additional stud-
ies are needed to help guide providers to select between oral 
fidaxomicin versus oral vancomycin. In adults, fidaxomicin 
was compared to vancomycin for the treatment of CDI in 
a prospective, multicenter, double-blind, parallel-group 
trial.47 Patients (n=629) who were 16 years or older with 
a confirmed diagnosis of CDI (ie, presence of diarrhea 
and C. difficile toxin A, B, or both in stool specimen) were 
stratified by their first or second episode of CDI. Those 
participants were also randomized to receive fidaxomicin 
(200 mg twice daily) or vancomycin (125 mg four times 
daily) orally for 10 days. Severity of CDI was not a criterion 
for inclusion. The primary end point was clinical cure, which 
was defined as a resolution of symptoms and no need for 
additional therapy for CDI as of the second day after the 
end of the treatment course. Secondary end points were 
recurrence of CDI (diarrhea and positive stool toxin test 
within 4 weeks after treatment) and global cure. A total of 
548 out of the 629 patients enrolled were evaluated for the 
per-protocol analysis. Fidaxomicin was found to be nonin-
ferior to vancomycin (92.1% and 89.8%, respectively) in 
the rates of clinical cure. In addition, fidaxomicin resulted 
in a significantly lower rate of recurrence (13.3% vs 24.0%, 
p=0.04), including the patients with non-NAP1 strain, and 
improved rate of global cure (77.7% vs 67.1%, p=0.006). 
These conclusions were confirmed in both the per-protocol 
and the modified intention-to-treat analysis.47
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Economics
CDI is associated with a high monetary cost to the health 
care system and is a cause of significant morbidity and com-
plications that can affect mortality. In 2013, the US Centers 
for Disease Control and Prevention reported that C. difficile 
poses an immediate public health threat. The average cost for 
CDI management from hospitalizations, follow-up care, and 
drug treatment between 2005 and 2015 was ~US$63,000. The 
attributable cost of hospital-onset CDI was 1.5 times the cost 
of community-onset cases (US$34,157 vs US$20,095).48 On 
the other hand, CDI is estimated to cost Europe €3 billion/y 
in direct costs from health care services and has the potential 
to almost double over the next 4 decades.49 A recent study by 
Asensio et al50 showed that the length of stay attributable to 
CDI was about 5 days in children living in Spain and Italy, 
and the total attributable cost was €3,545 per patient.
The cost of medications also plays into the overall cost 
of treating pediatric patients with CDI. Commercially avail-
able oral vancomycin costs ~US$71–US$143/d (depending 
on the dosing regimen chosen) compared to only US$2/d 
with oral metronidazole.24,51 Even though oral vancomycin 
can be compounded extemporaneously, which can reduce 
cost, there is still a significant price difference compared to 
metronidazole, which can affect compliance.24 Oral fidax-
omicin costs ~US$335/d, which makes it the most expensive 
currently available CDI treatment.51 However, economic 
calculations often include additional factors besides the cost 
of the drug treatment when assessing the cost-effectiveness 
of a medication.
Cost-effectiveness data in pediatrics are lacking and the fol-
lowing are some adult data. Thomas et al52 compared the drug 
costs of oral vancomycin and oral metronidazole in a model 
that factored in a resistance rate to metronidazole of 20%. The 
study calculated the average cost of metronidazole treatment to 
be less than that of vancomycin (US$561 vs US$910, respec-
tively). Costs would be equivalent between the two treatments 
only once metronidazole resistance rates reached 75%. In 
addition, vancomycin would achieve economic superiority if 
drug costs were able to be reduced by 88%. Limitations of this 
study are that the cost-effectiveness model did not define or 
account for disease severity and that the study did not include 
all direct and indirect costs for CDI treatment.52
A 2011 meta-analysis conducted in Canada included 
direct costs of CDI to the health care system (ie, hospital 
costs, physician payments, and diagnostic tests) and direct 
costs to the patients (ie, copayments).53 The calculated cost 
assumed that both metronidazole and vancomycin were given 
as the commercially available oral capsules. The  average 
cost per case was Canadian dollar (CAD) 36,018 with 
metronidazole and CAD 36,250 with vancomycin, favoring 
metronidazole by CAD 232. An additional sensitivity analy-
sis was completed to assess more difficult-to-treat isolates, 
which factored in estimated effectiveness (metronidazole 
0.42 vs vancomycin 0.60) and the cost of the compounded 
vancomycin formulation. This analysis found the average 
cost of metronidazole to be CAD 36,464 and vancomycin to 
be CAD 33,465, which they attributed to a decreased length 
of hospital stay in patients treated with vancomycin. One 
limitation of this meta-analysis is that the studies that were 
included had small sample sizes, which could have influenced 
the calculated cost differences.53
After fidaxomicin received approval for the treatment of 
CDI, many payers and providers were interested to see how 
its costs compared to the costs of other standard-of-care 
medications. Gallagher et al54 evaluated patients (n=95, mean 
age: 72.1 years) who had received treatment for an initial 
CDI with vancomycin or fidaxomicin and calculated the 
average cost per patient. The total cost for each medication 
accounted for drug costs, hospital admission charges, and 
insurance reimbursements for any readmissions. The total 
drug costs for fidaxomicin and vancomycin were US$62,112 
and US$6,646, respectively. Compared to vancomycin, 
fidaxomicin had a lower rate of recurrence and readmissions 
and saved the hospital ~US$142,507. By looking only at 
the considerable decrease in readmissions and cost savings, 
fidaxomicin was recommended to be used as first-line treat-
ment over vancomycin.54
The British Society of Antimicrobial Chemotherapy55 
also conducted a cost-effectiveness analysis of fidaxomicin 
versus vancomycin, which included patients with severe CDI 
and patients with their first CDI recurrence.55 A 1-year time 
horizon Markov model utilized effectiveness, resource use, 
direct costs, and utilities from published sources and a Scot-
tish expert panel. The main model outcome for the two treat-
ments was the ICER, which was expressed as cost per QALY. 
Patients with severe CDI had similar total treatment costs 
with fidaxomicin and vancomycin (£14,515 and £14,344, 
respectively). In patients with a first recurrence, treatment 
with fidaxomicin was less expensive than with vancomycin 
(£16,535 and £16,926, respectively). Fidaxomicin was cost-
effective in severe CDI (ICER £16,529/QALY) and dominant 
in effectiveness and cost in patients with a first recurrence 
due to improvement in clinical outcomes. Interpreting cost-
effectiveness using a willingness-to-pay threshold of £30,000/
QALY showed that fidaxomicin was cost-effective for 60% 
of severe CDI and 68% of first recurrences.55
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A recent decision analysis compared four different treat-
ment options, namely, metronidazole, vancomycin, fidaxomi-
cin, and FMT, for recurrent CDI in adults. This study found 
that FMT colonoscopy was the most cost-effective.56 FMT 
colonoscopy is not very well studied in pediatric patients and 
is not without risk. For settings where FMT is not applicable, 
the authors concluded that the preferred strategy to treat an 
initial recurrent infection is with oral vancomycin. The deci-
sion analysis results suggested that fidaxomicin is not cur-
rently a cost-effective option and would require a 35%–51% 
decrease in drug cost (ie, <US$1,359) to be cost-effective.56
All the current data on the cost attributable to pediatric 
CDI failed to account for the parental cost of loss of earning, 
in addition to the cost of child care for the rest of the family. 
This speculation or assumption can surely add to the overall 
cost of treating pediatric patients with CDI in the hospital 
setting. Even though some of the therapies mentioned earlier 
are more costly than the others, the cost should be minor 
compared with effective clinical outcomes and the ability to 
prevent recurrence; so using an agent that has been shown 
to combat this potentially life-threatening condition should 
have the utmost priority.
Current clinical application
Metronidazole should continue to serve as the first-line 
agent for initial and first recurrence of mild-to-moderate 
severity in pediatric patients with CDI. For patients who 
have an underlying infection for which prolonged non-CDI 
antibiotics are required, an additional week of CDI treatment 
may help reduce the risk of recurrence.18 Current guidelines 
by the American College of Gastroenterology recommend 
switching to oral vancomycin therapy for patients who are 
not responding to oral metronidazole after 5–7 days of 
treatment.57 Future studies should evaluate whether met-
ronidazole should be given every 8 hours instead of every 
6 hours for CDI in pediatric patients due to its concentration-
dependent bactericidal activity and prolonged half-life. If 
patients are on vancomycin therapy and do not demonstrate 
clinical improvement within 24–48 hours or for patients 
who develop complications, the dose of oral vancomycin 
can be increased to a maximum of 500 mg every 6 hours in 
adults, although the supportive evidence of this higher dose 
is lacking in pediatric patients. After 3–5 days of treatment 
with oral vancomycin at this higher dose, it is appropriate 
to complete a laboratory draw and assess the concentration 
of vancomycin in the serum. Some uncertainties with oral 
vancomycin are the use of pulse and rectal drug dosing; 
further studies are needed to evaluate such practices in the 
pediatric population.
At this time, fidaxomicin has not been approved for the 
treatment of moderate-to-severe CDI in children, and there 
are limited data that demonstrate safe and effective use of 
this medication in children. However, the case report pre-
viously mentioned is a great example of a type of patient 
who may benefit from fidaxomicin.46 Fidaxomicin could 
potentially be considered once a pediatric patient has failed 
treatment with oral metronidazole and oral vancomycin and 
is still having recurrence of moderate-to-severe CDI. A gap 
in knowledge still remains as regards the use of fidaxomicin 
in pediatric patients, and more studies need to be completed 
before using it as the standard of care for this population. A 
Phase IIA, multicenter, open-label, uncontrolled study has 
recently been performed evaluating the safety, tolerability, 
and pharmacokinetics of fidaxomicin in patients between 
6 months and 17 years of age.41 Patients were given 16 mg/kg 
per dose (maximum dose of 200 mg) orally every 12 hours, 
whereas patients aged 6 years to <18 years were given 200 mg 
every 12 hours; the duration of therapy for both groups was 
10 days. Thirty eight patients were enrolled into this study. 
The data collection of this study has been completed and 
is pending publication.41 Astellas Pharma Inc and Merck 
Sharp & Dohme Corp are also currently studying an oral 
suspension formulation of fidaxomicin in an ongoing clinical 
trial comparing the safety and efficacy of fidaxomicin and 
vancomycin in pediatric patients with CDI.58 All these new 
data will surely enhance the potential usage of fidaxomicin 
for CDI in the pediatric population.
More CDI-based clinical trials are being conducted in 
pediatric patients. Of interest, investigators are evaluating 
the use of a new monoclonal antibody bezlotoxumab (MK-
6072) in children with CDI.59 This medication is already 
being used in the adult population for the prevention of 
recurrent CDI.60 This is a Phase III, randomized, double-
blind, placebo-controlled trial evaluating the safety, toler-
ability, pharmacokinetics, and efficacy of a single infusion 
of bezlotoxumab in children aged 1 year to <18 years with a 
confirmed diagnosis of CDI. The investigators will evaluate 
the concentration–time curve and AUC as few of the primary 
end points. They will also look at the recurrence rate of CDI 
and sustained clinical response (up to 12 weeks) after being 
on this therapy. This study is in the recruiting process, and 
if the results are positive, bezlotoxumab may potentially be 
added to the armamentarium of clinicians for preventing or 
treating pediatric patients with severe, recurrent CDI.59
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Conclusion
Metronidazole and vancomycin are still the standard of care 
for the treatment of pediatric patients with CDI. Even though 
the data for their use in children are lacking, their proven effi-
cacy and tolerability are mainly extrapolated from previously 
reported adult data and guidelines. Fidaxomicin provides an 
additional therapeutic option for patients with recurrent CDI. 
Studies that are available thus far show that fidaxomicin is 
well tolerated in pediatric patients and is effective at achiev-
ing clinical cure and preventing recurrent infections. Its use 
should be limited to cases of drug-resistant C. difficile isolates 
and refractory patients at this time. Clinicians may potentially 
refer to the adult recommended dosing for children older than 
6 years of age. Further studies are needed to get fidaxomicin 
approved for use in patients <18 years old and to understand 
its role in the standard of care for pediatric patients with CDI.
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